Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mustafa Çoban, Uğur Bilge, Hale Balseven, Hilmi Uysal & Betül Artut. (2023) The economic evaluation of ALS care: quality and cost. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:5-6, pages 502-513.
Read now
Read now
Kate T. Brizzi, John F. P. Bridges, Jill Yersak, Calaneet Balas, Neil Thakur, Miriam Galvin, Orla Hardiman, Chad Heatwole, John Ravits, Zachary Simmons, Lucie Bruijn, James Chan, Richard Bedlack & James D. Berry. (2020) Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:5-6, pages 355-363.
Read now
Read now
Giuseppe Fiorentino & Antonio M. Esquinas. (2018) Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 315-316.
Read now
Read now
Lisa Meng, Amy Bian, Scott Jordan, Andrew Wolff, Jeremy M. Shefner & Jinsy Andrews. (2018) Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:1-2, pages 134-142.
Read now
Read now
Articles from other publishers (10)
Christopher Galvin, Winni Yang & Altaf Saadi. (2023) Evaluation of Crowdsourced Fundraising to Cover Health Care Costs for Neurological Conditions in the US. JAMA Neurology.
Crossref
Crossref
Kate Brizzi. 2023. Neuropalliative Care, Part II. Neuropalliative Care, Part II
29
48
.
Diane B. Re, Beizhan Yan, Lilian Calderón-Garcidueñas, Angeline S. Andrew, Maeve Tischbein & Elijah W. Stommel. (2022) A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk. Journal of Neurology 269:5, pages 2359-2377.
Crossref
Crossref
Spyros Papapetropoulos, Angela Pontius, Elizabeth Finger, Virginija Karrenbauer, David S. Lynch, Matthew Brennan, Samantha Zappia, Wolfgang Koehler, Ludger Schoels, Stefanie N. Hayer, Takuya Konno, Takeshi Ikeuchi, Troy Lund, Jennifer Orthmann-Murphy, Florian Eichler & Zbigniew K. Wszolek. (2022) Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development. Frontiers in Neurology 12.
Crossref
Crossref
K. Achtert & L. Kerkemeyer. (2021) The economic burden of amyotrophic lateral sclerosis: a systematic review. The European Journal of Health Economics 22:8, pages 1151-1166.
Crossref
Crossref
Nimish J. Thakore, Erik P. Pioro, Belinda L. Udeh, Brittany R. Lapin & Irene L. Katzan. (2020) A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. Value in Health 23:12, pages 1543-1551.
Crossref
Crossref
Paul Mehta, D. Kevin Horton, Edward J. Kasarskis, Ed Tessaro, M. Shira Eisenberg, Susan Laird & John Iskander. (2017) CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions. MMWR. Morbidity and Mortality Weekly Report 66:50, pages 1379-1382.
Crossref
Crossref
Alan Moore, Carolyn A. Young & Dyfrig A. Hughes. (2016) Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. PharmacoEconomics 35:4, pages 397-413.
Crossref
Crossref
Bert Tuk, Harmen Jousma & Pieter J. Gaillard. (2017) Treatment with penicillin G and hydrocortisone reduces ALS-associated symptoms: a case series of three patients. F1000Research 6, pages 410.
Crossref
Crossref
Federica Edith Pisa, Giancarlo Logroscino, Paolo Giacomelli Battiston & Fabio Barbone. (2016) Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study. BMC Pulmonary Medicine 16:1.
Crossref
Crossref